Track market-moving stories before they get noisy

Eastern Bankshares, Inc. (EBC) Q3 2026 Earnings Call October 23, 2026 9:00 AM EDT

Company Participants

Denis Sheahan - CEO & Director
R. Rosato - CFO & Treasurer

Conference Call Participants

Damon Del Monte - Keefe, Bruyette, & Woods, Inc., Research Division
Justin Crowley - Piper Sandler & Co., Research Division
Feddie Strickland - Hovde Group, LLC, Research Division
Tyler Cacciatori - Stephens Inc.
Laura Havener Hunsicker - Seaport Research Partners
Jared David Shaw - Barclays Bank PLC, Research Division

Presentation

Operator

Welcome to the Eastern Bankshares, Inc. Third Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded for replay purposes. In connection with today's call, the company posted a presentation on its Investor Relations website, investor.easternbank.com.

Today's call will include forward-looking statements. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance. Please refer to the company's forward-looking statement on Slide 19 of this presentation as well as the risk factors described in the company's SEC filings. The company will also discuss both GAAP and certain non-GAAP financial measures. For reconciliations, please refer to the company's earnings press release and SEC filings.

I'd now like to turn the call over to Denis Sheahan, Eastern Chief Executive Officer.

Denis Sheahan
CEO & Director

Thank you. Good morning, everyone, and thank you for joining us. On the call today with me are Executive Chair and Chair of the Board of Directors, Bob Rivers; President and Chief Operating Officer, Quincy Miller; and our Chief Financial Officer, David Rosato. We're pleased with our third quarter performance, which reflects disciplined execution of our priorities. We delivered record operating earnings, generated attractive returns, maintained excellent asset quality and returned meaningful capital to shareholders, all while continuing to drive organic growth across both our banking and fee-based businesses.

BOSTON--(BUSINESS WIRE)--Eastern Bankshares, Inc. Reports Third Quarter 2026 Financial Results.

Eastern Bankshares, Inc. (EBC - Free Report) reported $306.6 million in revenue for the quarter ended September 2026, representing a year-over-year increase of 27%. EPS of $0.51 for the same period compares to $0.37 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $308.79 million, representing a surprise of -0.71%. The company delivered an EPS surprise of +4.08%, with the consensus EPS estimate being $0.49.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Eastern Bankshares performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Efficiency ratio (GAAP): 52.1% versus 52.6% estimated by four analysts on average.Net interest margin (FTE): 3.6% versus the three-analyst average estimate of 3.7%.Average Balance - Total interest-earning assets: $28.84 billion versus $28.89 billion estimated by two analysts on average.Total Noninterest Income: $48.7 million versus $50.03 million estimated by four analysts on average.Net Interest Income: $257.9 million versus the three-analyst average estimate of $257.88 million.Net Interest Income (FTE): $263 million versus $264.14 million estimated by two analysts on average.View all Key Company Metrics for Eastern Bankshares here>>>

Shares of Eastern Bankshares have returned +1.8% over the past month versus the Zacks S&P 500 composite's no change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentation

Updated first-line data for olomorasib, an investigational therapy targeting KRAS G12C-mutant NSCLC, to be featured in a rapid oral presentation

Updated Phase 3 data for selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant MTC to be shared in a proffered paper

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 in Madrid, Spain. Highlights include new Phase 1 data in platinum-sensitive ovarian cancer (PSOC) for sofetabart mipitecan (Sofe-M), Lilly's investigational FRα-targeting antibody-drug conjugate (ADC), in combination with bevacizumab, along with updated findings for olomorasib, Retevmo (selpercatinib), and Verzenio (abemaciclib) in lung, thyroid, and breast cancers, respectively.

Key Presentation Highlights:

Sofetabart mipitecan (Sofe-M; FRα-targeting ADC): A rapid oral presentation on first Phase 1 data for sofetabart mipitecan plus bevacizumab in patients with PSOC. These data support the ongoing Phase 3 clinical trial of Sofe-M in PSOC.

Olomorasib (investigational KRAS G12C inhibitor):
A rapid oral presentation on an updated integrated analysis from the Phase 1/2 LOXO-RAS-20001 trial and the safety lead-in portion of the Phase 3 SUNRAY-01 trial, assessing olomorasib in combination with chemoimmunotherapy (pembrolizumab, pemetrexed, and platinum) as potential first-line treatments for patients with advanced/metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC). These data support the ongoing Phase 3 clinical trial of olomorasib in first-line KRAS G12C-mutant lung cancer.

Retevmo (selpercatinib; RET kinase inhibitor): A proffered paper presentation on updated results from the Phase 3 LIBRETTO-531 study of selpercatinib versus cabozantinib or vandetanib (C/V) in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer (MTC). These data have supported global approvals of Retevmo in this treatment setting.

Verzenio (abemaciclib; CDK4/6 inhibitor): A rapid oral presentation on overall survival data from the Phase 3 postMONARCH trial of abemaciclib plus fulvestrant in HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor and endocrine therapy. These data support the abemaciclib plus imlunestrant results in the EMBER-3 trial and add to the evidence-based practice of switching endocrine therapy and CDK4/6 inhibitor at progression in metastatic breast cancer.

"Lilly's presentations at ESMO reflect both the breadth of our oncology portfolio and the focus behind it: following compelling science wherever it has the potential to change care," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "We're especially encouraged by the data we're sharing for sofetabart mipitecan in platinum-sensitive ovarian cancer, which build on what we've seen with this medicine in platinum-resistant disease and mark a critical step forward as we advance the ongoing Phase 3 FRAmework-01 study across both settings. Our updated first-line data for olomorasib in KRAS G12C-mutant lung cancer are very promising, with clinical activity and a safety profile consistent with earlier findings, which reinforce the importance of targeted therapy for patients from the outset of their treatment journey. Alongside new data in thyroid and breast cancers, these presentations represent meaningful momentum toward improving care for people with cancer."

A full list of abstract titles and viewing details are listed below:

Abstract Title

Author

Presentation
Type/#

Session Title

Session Date/Time

(CET)

Sofe-M (sofetabart mipitecan; investigational ADC targeting FRα):

Model-informed Phase 3 dose
selection for antibody-drug conjugate
(ADC) sofetabart mipitecan (Sofe-M):
First prospective application of a
clinical utility index (CUI)

Jean-
Sebastien
Frenel

Poster
#1016P

Poster display
session

Friday, October 23

15:15-16:00

Efficacy and safety
of sofetabart mipitecan (Sofe-M), a
folate receptor alpha (FRα) targeting
antibody drug conjugate (ADC), plus
bevacizumab in recurrent platinum
sensitive ovarian cancer (PSOC)

Chrisann Kyi

Rapid oral
#1246RO

Rapid oral 2:
Gynecological
cancers

Saturday, October 24

8:30-10:00

Sofetabart mipitecan (Sofe-M) in
patients ≥65 y with platinum-resistant
and -sensitive ovarian cancer
(PROC/PSOC) from the first-in-human
phase 1 study

Ana Oaknin

Poster
#1288P

Poster display
session

Monday, October 26

12:00-12:45

Olomorasib (investigational KRAS G12C inhibitor)

First-line (1L) olomorasib +
chemoimmunotherapy (Chemo-IO) in
KRAS G12C-mutant NSCLC: Updated
results from the LOXO-RAS-20001 and
SUNRAY-01 trials

Marcelo V.
Negrao

Rapid oral
#2652RO

Rapid oral 2:
NSCLC, metastatic

Sunday,

October 25

8:30-10:00

First-line (1L) olomorasib +
pembrolizumab in KRAS G12C-mutant
NSCLC: Updated results from LOXO-
RAS-20001 and SUNRAY-01

Melissa L.
Johnson

Poster
#2683P

Poster display
session

Monday, October 26

12:00-12:45

Retevmo (selpercatinib; RET kinase inhibitor)

Updated results of randomized Phase
3 study of selpercatinib vs
cabozantinib or vandetanib (C/V) in
advanced, kinase inhibitor-naïve, RET-
mutant medullary thyroid cancer
(MTC)

Jaume
Capdevila

Proffered paper
#4208O

Proffered paper:
NETs and
endocrine tumors

Monday, October 26

10:15-11:45

Verzenio (abemaciclib; CDK4/6 inhibitor)

Association of p27 V109G SNP zygosity
with outcomes
and abemaciclib treatment effect in
HR+, HER2– high-risk early breast
cancer: results from monarchE

Miguel
Quintela-
Fandino

Poster
#4498P

Poster display
session

Friday, October 23

15:15-16:00

Overall survival from the Phase
3 postMONARCH trial of abemaciclib +
fulvestrant vs placebo + fulvestrant for
HR+, HER2– advanced breast cancer
following progression on a prior
CDK4/6 inhibitor + endocrine therapy

Kevin Kalinsky

Rapid oral
#1RO

Rapid oral 1:
Breast cancer,
advanced stage

Saturday, October 24

10:15-11:45

Three-month persistence and
adherence to adjuvant abemaciclib in
high-risk HR+, HER2– early breast
cancer: real world data from ABSIDE-S

Isabel Blancas
López-Barajas

ePoster
#1933eP

ePoster session

Friday, October 23

8:00

Treatment persistence and clinical
characteristics in patients with HR+,
HER2–, high-risk early breast cancer
(EBC) treated with abemaciclib: A
multi-country real-world study

Hitomi Sakai

ePoster
#615eP

ePoster session

Friday, October 23

8:00

For more information on Lilly's oncology pipeline, click here.

About Sofetabart Mipitecan
Sofetabart mipitecan (Sofe-M; LY4170156) is composed of an Fc-silent, folate receptor alpha (FRα) specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker (PSARlink). Sofe-M was designed to target FRα across all expression levels with an improved therapeutic index. FRα is a cell-surface glycoprotein encoded by the gene FOLR1 that binds to the essential nutrients folic acid and reduced folates, bringing them into cells to facilitate cell division and growth.1,2 FRα is overexpressed in many solid tumors such as ovarian and endometrial cancers.1,3,4 Sofe-M has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for platinum-resistant ovarian cancer (PROC) and is currently being evaluated in the Phase 3 FRAmework-01 trial. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT – lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).

About Olomorasib
Olomorasib (LY3537982) is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. KRAS is the most common oncogene across all tumor types, and KRAS G12C mutations occur in 13% of patients with non-small cell lung cancer (NSCLC), and 1–3% of patients with other solid tumors.5 Olomorasib is a highly potent covalent inhibitor with potential for greater than 90% target occupancy, which may allow for safer combinations with less toxicity.6

Olomorasib is currently being studied in KRAS G12C-mutant cancers in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced NSCLC, in combination with immunotherapy for the treatment of resected and unresectable NSCLC, and as monotherapy and in combinations in other advanced solid tumors (NCT06119581, NCT06890598, and NCT04956640).

About Retevmo
Retevmo (selpercatinib, formerly known as LOXO-292) (pronounced reh-TEHV-moh) is a highly selective and potent RET kinase inhibitor with central nervous system (CNS) activity. Retevmo may affect both tumor cells and healthy cells, which can result in side effects. RET-driver alterations are predominantly mutually exclusive from other oncogenic drivers. Retevmo is a U.S. FDA-approved oral prescription medicine, 120 mg or 160 mg dependent on weight (<50 kg or ≥50 kg, respectively), taken twice daily until disease progression or unacceptable toxicity.7

INDICATIONS FOR RETEVMO (selpercatinib)
RETEVMO is a kinase inhibitor indicated for the treatment of:

Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapyIMPORTANT SAFETY INFORMATION FOR RETEVMO (selpercatinib)

Hepatotoxicity: Serious hepatic adverse reactions occurred in 4.6% of patients treated with Retevmo. Increased aspartate aminotransferase (AST) occurred in 62% of patients, including Grade 3 or 4 events in 11% and increased alanine aminotransferase (ALT) occurred in 58% of patients, including Grade 3 or 4 events in 13%. Monitor ALT and AST prior to initiating Retevmo, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce dose, or permanently discontinue Retevmo based on severity.

Severe, life-threatening, and fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with Retevmo. ILD/pneumonitis occurred in 3% of patients who received Retevmo, including 0.3% with Grade 3 or 4 events, and 0.2% with fatal reactions. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold Retevmo and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Withhold, reduce dose, or permanently discontinue Retevmo based on severity of confirmed ILD.

Hypertension occurred in 43% of patients, including Grade 3 hypertension in 20% and Grade 4 in one (0.1%) patient. Overall, 6.4% had their dose interrupted, 1.5% had their dose reduced, and 0.2% discontinued Retevmo for hypertension. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications. Do not initiate Retevmo in patients with uncontrolled hypertension. Optimize blood pressure prior to initiating Retevmo. Monitor blood pressure after 1 week, at least monthly thereafter, and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue Retevmo based on severity.

Retevmo can cause concentration-dependent QT interval prolongation. An increase in QTcF interval to >500 ms was measured in 8% of patients and an increase in the QTcF interval of at least 60 ms over baseline was measured in 22% of patients. Retevmo has not been studied in patients with clinically significant active cardiovascular disease or recent myocardial infarction. Monitor patients who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, and severe or uncontrolled heart failure. Assess QT interval, electrolytes, and thyroid-stimulating hormone (TSH) at baseline and periodically during treatment, adjusting frequency based upon risk factors including diarrhea.

Correct hypokalemia, hypomagnesemia, and hypocalcemia prior to initiating Retevmo and during treatment. Monitor the QT interval more frequently when Retevmo is concomitantly administered with strong and moderate CYP3A inhibitors or drugs known to prolong QTc interval. Withhold and dose reduce or permanently discontinue Retevmo based on the severity.

Serious, including fatal, hemorrhagic events can occur with Retevmo. Grade ≥3 hemorrhagic events occurred in 4.3% of patients treated with Retevmo including 4 (0.5%) patients with fatal hemorrhagic events, including cerebral hemorrhage (n=2), tracheostomy site hemorrhage and hemoptysis (1 each). Permanently discontinue Retevmo in patients with severe or life-threatening hemorrhage.

Retevmo can cause hypersensitivity, including severe skin reactions such as Stevens-Johnson Syndrome. All grade hypersensitivity occurred in 6% of patients receiving Retevmo, including Grade 3 in 2%. The median time to onset was 1.9 weeks (range: 5 days to 6.5 years). Signs and symptoms of hypersensitivity included fever, rash and arthralgias or myalgias with concurrent decreased platelets or transaminitis. Stevens-Johnson Syndrome has been observed in the post-marketing setting. Discontinue Retevmo in patients with Stevens-Johnson Syndrome. If hypersensitivity occurs, withhold Retevmo and begin corticosteroids at a dose of 1 mg/kg prednisone (or equivalent). Upon resolution of the event, resume Retevmo at a reduced dose and increase the dose of Retevmo by 1 dose level each week as tolerated until reaching the dose taken prior to onset of hypersensitivity. Continue steroids until patient reaches target dose and then taper. Permanently discontinue Retevmo for recurrent hypersensitivity.

Tumor lysis syndrome (TLS) occurred in 0.9% of patients with medullary thyroid carcinoma and 0.3% of patients with non-small cell lung cancer receiving Retevmo. Patients may be at risk of TLS if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration. Closely monitor patients at risk, consider appropriate prophylaxis including hydration, and treat as clinically indicated.

Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, Retevmo has the potential to adversely affect wound healing. Withhold Retevmo for at least 7 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of Retevmo after resolution of wound healing complications has not been established.

Retevmo can cause hypothyroidism. Hypothyroidism occurred in 15% of patients treated with Retevmo; all reactions were Grade 1 or 2. Hypothyroidism occurred in 15% of patients (59/390) with thyroid cancer and 14% of patients (65/467) with other solid tumors including NSCLC. Monitor thyroid function before treatment with Retevmo and periodically during treatment. Treat with thyroid hormone replacement as clinically indicated. Withhold Retevmo until clinically stable or permanently discontinue Retevmo based on severity.

Based on data from animal reproduction studies and its mechanism of action, Retevmo can cause fetal harm when administered to a pregnant woman. Administration of selpercatinib to pregnant rats during organogenesis at maternal exposures that were approximately equal to those observed at the recommended human dose of 160 mg twice daily resulted in embryolethality and malformations. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Retevmo and for 1 week after the last dose. There are no data on the presence of selpercatinib or its metabolites in human milk or on their effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with Retevmo and for 1 week after the last dose.

Slipped capital femoral epiphysis/slipped upper femoral epiphysis in pediatric patients (SCFE/SUFE) occurred in 1 adolescent (2.8% of 36 patients) receiving Retevmo in LIBRETTO-121 and 1 adolescent patient (0.5% of 193 patients) receiving Retevmo in LIBRETTO-531. Monitor patients for symptoms indicative of SCFE/SUFE and treat as medically and surgically appropriate.

Severe adverse reactions (Grade 3-4) occurring in ≥20% of patients who received Retevmo in LIBRETTO-001 were hypertension (20%), diarrhea (6.2%), prolonged QT interval (5%), fatigue (4.7%), musculoskeletal pain (4.1%), dyspnea (4.1%), hemorrhage (3.9%), abdominal pain (3.5%), vomiting (2.9%), urinary tract infection (2.2%), nausea (1.9%), headache (1.8%), edema (1.3%), decreased appetite (0.9%), constipation (0.8%), rash (0.8%), and dizziness (0.5%).

Severe adverse reactions (Grade 3-4) occurring in ≥15% of patients who received Retevmo in LIBRETTO-121 were increased weight (11%), vomiting (8%), constipation (6%), diarrhea (2.8%), nausea (2.8%), upper respiratory tract infection (2.8%), and urinary tract infection (2.8%).

Severe adverse reactions (Grade 3-4) occurring in ≥15% of patients who received Retevmo or chemotherapy with or without pembrolizumab in LIBRETTO-431 were hypertension (20% vs 3.1%), electrocardiogram QT prolonged (9% vs 0%), fatigue (3.2% vs 5%), edema (2.5% vs 0%), rash (1.9% vs 1.0%), diarrhea (1.3% vs 2.0%), abdominal pain (0.6% vs 2.0%), pyrexia (0.6% vs 0%), COVID19 infection (0.6% vs 0%), constipation (0% vs 1.0%), nausea (0% vs 1.0%), vomiting (0% vs 1.0%), and decreased appetite (0% vs 2.0%).

Severe adverse reactions (Grade 3-4) occurring in ≥10% of patients who received Retevmo in LIBRETTO-531 were (Retevmo vs cabozantinib / vandetanib) hypertension (19% vs 18%), electrocardiogram QT prolonged (4.7% vs 2.1%), fatigue (4.1% vs 9%), diarrhea (3.1% vs 8%), rash (1.6% vs 4.1%), pyrexia (1.0% vs 0%), nausea (1.0% vs 5%), dry mouth (0.5% vs 1.0%), abdominal pain (0.5% vs 2.1%), stomatitis (0.5% vs 13%), headache (0.5% vs 0%), and decreased appetite (0.5% vs 5%).

Serious adverse reactions occurred in 58% of patients who received Retevmo in LIBRETTO-001. The most frequently reported serious adverse reactions (in ≥2% of patients) were pneumonia, hemorrhage, abdominal pain, dyspnea, pleural effusion, sepsis, musculoskeletal pain, hyponatremia, vomiting, diarrhea, and increased blood creatinine. Fatal adverse reactions occurred in 3% of patients in LIBRETTO-001; fatal adverse reactions included sepsis (n=6), respiratory failure (n=5), hemorrhage (n=4), pneumonia (n=4), cardiac arrest (n=3), pneumonitis (n=2), cardiac failure (n=2), sudden death (n=1), cerebral infarction (n=1), and dyspnea (n=1).

Serious adverse reactions occurred in 42% of patients who received Retevmo in LIBRETTO-121. Serious adverse reactions occurring in more than 1 patient were vomiting and fracture (2 patients each).

Serious adverse reactions occurred in 35% of patients who received Retevmo in LIBRETTO-431. The most frequently reported serious adverse reactions (≥2% of patients) were pleural effusion and abnormal hepatic function. Fatal adverse reactions occurred in 4.4% of patients who received Retevmo in LIBRETTO-431; fatal adverse reactions included myocardial infarction (n=2), respiratory failure (n=2), cardiac arrest, malnutrition, and sudden death (n=1 each).

Serious adverse reactions occurred in 22% of patients who received Retevmo in LIBRETTO-531. The most frequent serious adverse reactions were pneumonia and pyrexia (n=3 each), and hypertension and urinary tract infection (n=2 each). Fatal adverse reactions occurred in 2.1% of patients who received Retevmo in LIBRETTO-531; fatal adverse reactions included COVID19, diabetic ketoacidosis, multiple organ dysfunction syndrome, and sudden death (n=1 each).

Common adverse reactions (all grades) occurring in ≥20% of patients who received Retevmo in LIBRETTO-001 were musculoskeletal pain (59%), edema (53%), diarrhea (52%), fatigue (49%), dry mouth (44%), hypertension (43%), abdominal pain (39%), rash (38%), nausea (36%), constipation (35%), cough (30%), headache (30%), vomiting (29%), dyspnea (28%), hemorrhage (26%), decreased appetite (23%), dizziness (22%), prolonged QT interval (21%), and urinary tract infection (20%).

Common adverse reactions (all grades) occurring in ≥15% of patients who received Retevmo in LIBRETTO-121 were musculoskeletal pain (58%), diarrhea (47%), nausea (42%), hemorrhage (39%), pyrexia (39%), abdominal pain (36%), headache (33%), vomiting (31%), fatigue (31%), cough (31%), rash (28%), coronavirus infection (28%), upper respiratory tract infection (28%), edema (25%), constipation (22%), oropharyngeal pain (22%), hypothyroidism (22%), urinary tract infection (19%), and increased weight (19%).

Common adverse reactions (all grades) occurring in ≥15% of patients who received Retevmo or chemotherapy with or without pembrolizumab in LIBRETTO-431 were hypertension (48% vs 7%), diarrhea (44% vs 24%), edema (41% vs 28%), dry mouth (39% vs 6%), rash (33% vs 30%), fatigue (32% vs 50%), abdominal pain (25% vs 19%), musculoskeletal pain (25% vs 28%), constipation (22% vs 40%), electrocardiogram QT prolonged (20% vs 1.0%), COVID19 infection (19% vs 18%), stomatitis (18% vs 16%), decreased appetite (17% vs 34%), nausea (13% vs 44%), vomiting (13% vs 23%), and pyrexia (13% vs 23%).

Common adverse reactions (all grades) occurring in ≥10% of patients who received Retevmo in LIBRETTO-531 (Retevmo vs cabozantinib / vandetanib) were hypertension (43% vs 41%), edema (33% vs 5%), dry mouth (32% vs 10%), fatigue (28% vs 47%), diarrhea (26% vs 61%), headache (23% vs 21%), rash (19% vs 27%), abdominal pain (18% vs 21%), constipation (16% vs 12%), erectile dysfunction (16% vs 0%), stomatitis (14% vs 42%), electrocardiogram QT prolonged (14% vs 13%), pyrexia (12% vs 2.1%), decreased appetite (12% vs 28%), hypothyroidism (11% vs 21%), and nausea (10% vs 32%).

Laboratory abnormalities (all grades ≥20%; Grade 3-4) worsening from baseline in patients who received Retevmo in LIBRETTO-001, were increased AST (62%; 11%), decreased calcium (61%; 7%), decreased albumin (61%; 3.6%), increased ALT (58%; 13%), increased glucose (56%; 4.0%), decreased lymphocytes (56%; 22%), increased creatinine (51%; 3.6%), decreased sodium (49%; 13%), increased alkaline phosphatase (43%; 4.4%), decreased platelets (41%; 4.0%), increased potassium (39%; 3.5%), decreased glucose (39%; 1.5%), increased total cholesterol (37%; 1.7%), decreased magnesium (37%; 0.7%), decreased hemoglobin (36%; 4.1%), increased bilirubin (32%; 2.9%), decreased neutrophils (27%; 3.8%), and decreased phosphate (25%; 5%).

Laboratory abnormalities (all grades ≥15%; Grade 3-4) worsening from baseline in patients who received Retevmo in LIBRETTO-121 were decreased calcium (61%; 11%), increased ALT (58%; 8%), decreased albumin (53%; 0%), increased alkaline phosphatase (50%; 0%), increased AST (50%; 2.8%), increased bilirubin (31%; 2.8%), increased cholesterol (28%, 0%), decreased magnesium (28%; 6%), increased potassium (28%; 2.8%), increased creatinine (19%, 2.8%), decreased potassium (19%, 6%), decreased sodium (17%, 0%), decreased neutrophils (40%; 8%), decreased hemoglobin (36%; 11%), increased hemoglobin (33%, 2.8%), decreased platelets (28%; 2.8%), and decreased lymphocytes (28%; 14%).

Laboratory abnormalities (all grades ≥20%; Grade 3-4) worsening from baseline in patients who received Retevmo or chemotherapy with or without pembrolizumab in LIBRETTO-431 were increased ALT (81%; 21% vs 63%; 4.1%), increased AST (77%; 10% vs 46%; 0%), decreased calcium (53%; 1.9% vs 24%; 1.0%), decreased platelets (53%; 3.2% vs 39%; 5%), decreased lymphocytes (53%; 8% vs 64%; 15%), decreased neutrophils (53%; 2.0% vs 58%; 11%), increased bilirubin (52%; 1.3% vs 9%; 0%), increased alkaline phosphatase (35%; 1.3% vs 22%; 0%), decreased sodium (31%; 3.2% vs 41%; 2.1%), decreased albumin (25%; 0% vs 5%; 0%), increased blood creatinine (23%; 0% vs 21%; 0%), decreased hemoglobin (21%; 0% vs 91%; 5%), decreased potassium (17%; 1.3% vs 15%; 1.0%), and decreased magnesium (16%; 0.6% vs 8%; 0%).

Laboratory abnormalities (all grades ≥5%; Grade 3-4) worsening from baseline in patients who received Retevmo in LIBRETTO-531 (Retevmo vs cabozantinib / vandetanib) were decreased calcium (55%; 5% vs 62%; 11%), increased ALT (53%; 16% vs 72%; 7%), increased AST (47%; 5% vs 68%; 3.2%), decreased lymphocytes (41%; 18% vs 36%; 13%), increased alkaline phosphatase (37%; 6% vs 28%, 5%), increased bilirubin (32%; 1.1% vs 30%; 3.2%), decreased neutrophils (33%; 14% vs 42%; 19%), decreased platelets (28%; 1.1% vs 34%; 1.1%), increased creatinine (27%; 6% vs 16%; 8%), decreased sodium (20%; 3.2% vs 16%; 0%), decreased hemoglobin (18%; 2.1% vs 23%; 2.1%), decreased albumin (11%; 1.1% vs 7%; 0%), decreased magnesium (9%; 3.3% vs 26%; 9%), and decreased potassium (8%; 0% vs 22%; 4.4%).

Concomitant use of acid-reducing agents decreases selpercatinib plasma concentrations which may reduce Retevmo anti-tumor activity. Avoid concomitant use of proton-pump inhibitors (PPIs), histamine-2 (H2) receptor antagonists, and locally acting antacids with Retevmo. If coadministration cannot be avoided, take Retevmo with food (with a PPI) or modify its administration time (with a H2 receptor antagonist or a locally acting antacid).

Concomitant use of strong and moderate CYP3A inhibitors increases selpercatinib plasma concentrations which may increase the risk of Retevmo adverse reactions including QTc interval prolongation. Avoid concomitant use of strong and moderate CYP3A inhibitors with Retevmo. If concomitant use of a strong or moderate CYP3A inhibitor cannot be avoided, reduce the Retevmo dosage as recommended and monitor the QT interval with ECGs more frequently.

Concomitant use of strong and moderate CYP3A inducers decreases selpercatinib plasma concentrations which may reduce Retevmo anti-tumor activity. Avoid coadministration of Retevmo with strong and moderate CYP3A inducers.

Concomitant use of Retevmo with CYP2C8 and CYP3A substrates increases their plasma concentrations which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of Retevmo with CYP2C8 and CYP3A substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for CYP2C8 and CYP3A substrates provided in their approved product labeling.

Retevmo is a P-glycoprotein (P-gp) and BCRP inhibitor. Concomitant use of Retevmo with P-gp or BCRP substrates increases their plasma concentrations, which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of Retevmo with P-gp or BCRP substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for P-gp and BCRP substrates provided in their approved product labeling.

The safety and effectiveness of Retevmo have not been established in pediatric patients less than 2 years of age. The safety and effectiveness of Retevmo have been established in pediatric patients aged 2 years and older for the treatment of advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate), and locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

Monitor open growth plates in pediatric patients. Consider interrupting or discontinuing Retevmo if abnormalities occur.

No dosage modification is recommended for patients with mild to severe renal impairment (estimated Glomerular Filtration Rate [eGFR] ≥15 to 89 mL/min, estimated by Modification of Diet in Renal Disease [MDRD] equation). A recommended dosage has not been established for patients with end-stage renal disease.

Reduce the dose when administering Retevmo to patients with severe hepatic impairment (total bilirubin greater than 3 to 10 times upper limit of normal [ULN] and any AST). No dosage modification is recommended for patients with mild or moderate hepatic impairment. Monitor for Retevmo-related adverse reactions in patients with hepatic impairment.

Retevmo (selpercatinib) is available as 40 mg and 80 mg capsules, and 40 mg, 80 mg, 120 mg, and 160 mg tablets.

SE HCP ISI All_JUL2026

Please see full Prescribing Information and Instructions for Use for Retevmo.

About Verzenio (abemaciclib)
Verzenio (abemaciclib) is approved to treat people with certain HR+, HER2– breast cancers in the adjuvant and advanced or metastatic settings. Verzenio is an oral tablet taken twice daily and available in strengths of 50 mg, 100 mg, 150 mg, and 200 mg. Discovered and developed by Lilly researchers, Verzenio was first approved in 2017 and is authorized for use in more than 90 countries around the world. For full details on indicated uses of Verzenio in HR+, HER2– breast cancer, please see full Prescribing Information, available at www.Verzenio.com.

INDICATIONS FOR VERZENIO

Verzenio (abemaciclib) is a kinase inhibitor indicated8,9:

in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer.in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.in combination with Inluriyo for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.as monotherapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.IMPORTANT SAFETY INFORMATION FOR VERZENIO (abemaciclib)
Severe diarrhea associated with dehydration and infection occurred in patients treated with Verzenio. Across five clinical trials in 3899 patients, diarrhea occurred in 81% to 90% of patients who received Verzenio. Grade 3 diarrhea occurred in 8% to 20% of patients receiving Verzenio. Most patients experienced diarrhea during the first month of Verzenio treatment. The median time to onset of the first diarrhea event ranged from 6 to 8 days; and the median duration of Grade 2 and Grade 3 diarrhea ranged from 6 to 11 days and 5 to 8 days, respectively. Across trials, 19% to 26% of patients with diarrhea required a Verzenio dose interruption and 13% to 23% required a dose reduction.

Instruct patients to start antidiarrheal therapy such as loperamide at the first sign of loose stools, increase oral fluids, and notify their healthcare provider for further instructions and appropriate follow-up. For Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization, withhold Verzenio until resolution to ≤Grade 1, and then resume Verzenio at the next lower dose.

Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with Verzenio. Across five clinical trials in 3899 patients, neutropenia occurred in 37% to 51% of patients receiving Verzenio. A Grade ≥3 decrease in neutrophil count (based on laboratory findings) occurred in 19% to 32% of patients receiving Verzenio.

Across trials, the median time to first episode of Grade ≥3 neutropenia ranged from 29 days to 34 days, and the median duration of Grade ≥3 neutropenia ranged from 10 days to 16 days.

Febrile neutropenia has been reported in <1% of patients exposed to Verzenio across trials. Two deaths due to neutropenic sepsis were observed in MONARCH 2. Inform patients to promptly report any episodes of fever to their healthcare provider.

Monitor complete blood counts prior to the start of Verzenio therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.

Severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis can occur in patients treated with Verzenio and other CDK4/6 inhibitors. In Verzenio-treated patients in early breast cancer (monarchE, N=2791), 3% of patients experienced ILD or pneumonitis of any grade: 0.4% were Grade 3 or 4 and there was one fatality (0.1%). In Verzenio-treated patients in advanced or metastatic breast cancer (N=1108) (MONARCH 1, MONARCH 2, MONARCH 3, EMBER-3), 3.2% of Verzenio-treated patients had ILD or pneumonitis of any grade: 0.5% had Grade 3 or 4, and 0.5% had fatal outcomes. Additional cases of ILD or pneumonitis have been observed in the postmarketing setting, with fatalities reported.

Monitor patients for pulmonary symptoms indicative of ILD or pneumonitis. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations.

Withhold or reduce dose for patients who develop persistent or recurrent Grade 2 ILD or pneumonitis. Permanently discontinue VERZENIO in all patients with Grade 3 or 4 ILD or pneumonitis.

Grade ≥3 increases in alanine aminotransferase (ALT) (2% to 6%) and aspartate aminotransferase (AST) (2% to 3%) were reported in patients receiving Verzenio.

Across four clinical trials in 3767 patients (monarchE, MONARCH 2, MONARCH 3, EMBER-3), the median time to onset of Grade ≥3 ALT increases ranged from 57 to 87 days and the median time to resolution to Grade <3 was 13 to 14 days. The median time to onset of Grade ≥3 AST increases ranged from 71 to 185 days and the median time to resolution to Grade <3 ranged from 11 to 15 days.

Monitor liver function tests (LFTs) prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or any Grade 3 or Grade 4 hepatic transaminase elevation.

Venous thromboembolic events (VTE) were reported in 2% to 5% of patients treated with Verzenio across four clinical trials in 3767 patients (monarchE, MONARCH 2, MONARCH 3, EMBER-3). VTE events included deep vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, inferior vena cava thrombosis, jugular vein thrombosis, peripheral vein thrombosis and superficial vein thrombosis. In clinical trials, deaths due to VTE occurred in patients treated with Verzenio.

Verzenio has not been studied in patients with early breast cancer who had a history of VTE. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate. Dose interruption is recommended for early breast cancer patients with any grade VTE event and for advanced or metastatic breast cancer patients with a Grade 3 or 4 VTE event.

Verzenio can cause fetal harm when administered to a pregnant woman, based on findings from animal studies and the mechanism of action. In animal reproduction studies, administration of abemaciclib to pregnant rats during the period of organogenesis caused teratogenicity and decreased fetal weight at maternal exposures that were similar to the human clinical exposure based on area under the curve (AUC) at the maximum recommended human dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Verzenio and for 3 weeks after the last dose.

Verzenio can increase serum creatinine without affecting renal function. These increases were not associated with changes in glomerular function. In EMBER-3, creatinine increase occurred in 36% for all grades (Grade 3 or 4: 1.1%) of patients who received Inluriyo in combination with Verzenio. During Verzenio treatment, use alternative measures that are not based on serum creatinine to assess renal function such as BUN, cystatin C, or calculated GFR.

The most common adverse reactions (all grades, ≥10%) observed in monarchE for Verzenio plus tamoxifen or an aromatase inhibitor vs tamoxifen or an aromatase inhibitor, with a difference between arms of ≥2%, were diarrhea (84% vs 9%), infections (51% vs 39%), neutropenia (46% vs 6%), fatigue (41% vs 18%), leukopenia (38% vs 7%), nausea (30% vs 9%), anemia (24% vs 4%), headache (20% vs 15%), vomiting (18% vs 4.6%), stomatitis (14% vs 5%), lymphopenia (14% vs 3%), thrombocytopenia (13% vs 2%), decreased appetite (12% vs 2.4%), ALT increased (12% vs 6%), AST increased (12% vs 5%), dizziness (11% vs 7%), rash (11% vs 4.5%), and alopecia (11% vs 2.7%).

The most frequently reported ≥5% Grade 3 or 4 adverse reaction that occurred in the Verzenio arm vs the tamoxifen or an aromatase inhibitor arm of monarchE were neutropenia (19.6% vs 1%), leukopenia (11% vs <1%), diarrhea (8% vs 0.2%), and lymphopenia (5% vs <1%).

Lab abnormalities (all grades; Grade 3 or 4) for monarchE in ≥10% for Verzenio plus tamoxifen or an aromatase inhibitor with a difference between arms of ≥2% were increased serum creatinine (99% vs 91%; 0.5% vs <0.1%), decreased white blood cells (89% vs 28%; 19.1% vs 1.1%), decreased neutrophil count (84% vs 23%; 18.7% vs 1.9%), anemia (68% vs 17%; 1% vs .1%), decreased lymphocyte count (59% vs 24%; 13.2% vs 2.5%), decreased platelet count (37% vs 10%; .9% vs .2%), increased ALT (37% vs 24%; 2.6% vs 1.2%), increased AST (31% vs 18%; 1.6% vs .9%), and hypokalemia (11% vs 3.8%; 1.3% vs 0.2%).

The most common adverse reactions (all grades, ≥10%) observed in MONARCH 3 for Verzenio plus anastrozole or letrozole vs anastrozole or letrozole, with a difference between arms of ≥2%, were diarrhea (81% vs 30%), fatigue (40% vs 32%), neutropenia (41% vs 2%), infections (39% vs 29%), nausea (39% vs 20%), abdominal pain (29% vs 12%), vomiting (28% vs 12%), anemia (28% vs 5%), alopecia (27% vs 11%), decreased appetite (24% vs 9%), leukopenia (21% vs 2%), creatinine increased (19% vs 4%), constipation (16% vs 12%), ALT increased (16% vs 7%), AST increased (15% vs 7%), rash (14% vs 5%), pruritus (13% vs 9%), cough (13% vs 9%), dyspnea (12% vs 6%), dizziness (11% vs 9%), weight decreased (10% vs 3.1%), influenza-like illness (10% vs 8%), and thrombocytopenia (10% vs 2%).

The most frequently reported ≥5% Grade 3 or 4 adverse reactions that occurred in the Verzenio arm vs the placebo arm of MONARCH 3 were neutropenia (22% vs 1%), diarrhea (9% vs 1.2%), leukopenia (7% vs <1%)), increased ALT (6% vs 2%), and anemia (6% vs 1%).

Lab abnormalities (all grades; Grade 3 or 4) for MONARCH 3 in ≥10% for Verzenio plus anastrozole or letrozole with a difference between arms of ≥2% were increased serum creatinine (98% vs 84%; 2.2% vs 0%), decreased white blood cells (82% vs 27%; 13% vs 0.6%), anemia (82% vs 28%; 1.6% vs 0%), decreased neutrophil count (80% vs 21%; 21.9% vs 2.6%), decreased lymphocyte count (53% vs 26%; 7.6% vs 1.9%), decreased platelet count (36% vs 12%; 1.9% vs 0.6%), increased ALT (48% vs 25%; 6.6% vs 1.9%), and increased AST (37% vs 23%; 3.8% vs 0.6%).

The most common adverse reactions (all grades, ≥10%) observed in MONARCH 2 for Verzenio plus fulvestrant vs fulvestrant, with a difference between arms of ≥2%, were diarrhea (86% vs 25%), neutropenia (46% vs 4%), fatigue (46% vs 32%), nausea (45% vs 23%), infections (43% vs 25%), abdominal pain (35% vs 16%), anemia (29% vs 4%), leukopenia (28% vs 2%), decreased appetite (27% vs 12%), vomiting (26% vs 10%), headache (20% vs 15%), dysgeusia (18% vs 2.7%), thrombocytopenia (16% vs 3%), alopecia (16% vs 1.8%), stomatitis (15% vs 10%), ALT increased (13% vs 5%), pruritus (13% vs 6%), cough (13% vs 11%), dizziness (12% vs 6%), AST increased (12% vs 7%), peripheral edema (12% vs 7%), creatinine increased (12% vs <1%), rash (11% vs 4.5%), pyrexia (11% vs 6%), and weight decreased (10% vs 2.2%).

The most frequently reported ≥5% Grade 3 or 4 adverse reactions that occurred in the Verzenio arm vs the placebo arm of MONARCH 2 were neutropenia (25% vs 1%), diarrhea (13% vs 0.4%), leukopenia (9% vs 0%), anemia (7% vs 1%), and infections (5.7% vs 3.5%).

Lab abnormalities (all grades; Grade 3 or 4) for MONARCH 2 in ≥10% for Verzenio plus fulvestrant with a difference between arms of ≥2% were increased serum creatinine (98% vs 74%; 1.2% vs 0%), decreased white blood cells (90% vs 33%; 23.7% vs .9%), decreased neutrophil count (87% vs 30%; 32.5% vs 4.2%), anemia (84% vs 34%; 2.6% vs .5%), decreased lymphocyte count (63% vs 32%; 12.2% vs 1.8%), decreased platelet count (53% vs 15%; 2.1% vs 0%), increased ALT (41% vs 32%; 4.6% vs 1.4%), and increased AST (37% vs 25%; 3.9% vs 4.2%).

The most common adverse reactions (all grades, ≥10%) observed in MONARCH 1 with Verzenio were diarrhea (90%), fatigue (65%), nausea (64%), decreased appetite (45%), abdominal pain (39%), neutropenia (37%), vomiting (35%), infections (31%), anemia (25%), thrombocytopenia (20%), headache (20%), cough (19%), constipation (17%), leukopenia (17%), arthralgia (15%), dry mouth (14%), weight decreased (14%), stomatitis (14%), creatinine increased (13%), alopecia (12%), dysgeusia (12%), pyrexia (11%), dizziness (11%), and dehydration (10%).

The most frequently reported ≥5% Grade 3 or 4 adverse reactions from MONARCH 1 with Verzenio were diarrhea (20%), neutropenia (24%), fatigue (13%), and leukopenia (5%).

Lab abnormalities (all grades; Grade 3 or 4) for MONARCH 1 with Verzenio were increased serum creatinine (99%; .8%), decreased white blood cells (91%; 28%), decreased neutrophil count (88%; 26.6%), anemia (69%; 0%), decreased lymphocyte count (42%; 13.8%), decreased platelet count (41%; 2.3%), increased ALT (31%; 3.1%), and increased AST (30%; 3.8%).

Serious and Fatal Adverse Reactions for Inluriyo in combination with Verzenio: Serious adverse reactions occurred in 21% of patients who received Inluriyo in combination with Verzenio. Serious adverse reactions in >1% of patients who received Inluriyo in combination with Verzenio included pneumonia (2.4%), abdominal pain, and renal failure (each 1.4%). Fatal adverse reactions occurred in 3.8% of patients who received Inluriyo in combination with Verzenio, including pneumonia (1.4%), myocardial infarction, interstitial lung disease, and sepsis (0.5% each).

Most Common Adverse Reactions for Inluriyo in combination with Verzenio: The most common (≥10%) adverse reactions with Inluriyo in combination with Verzenio, including laboratory abnormalities, were decreased neutrophils, diarrhea, decreased hemoglobin, decreased lymphocytes, nausea, decreased platelets, fatigue, increased triglycerides, infections, increased AST, increased creatinine, increased ALT, vomiting, musculoskeletal pain, abdominal pain, decreased appetite, increased cholesterol, rash, cough, headache, and decreased weight.

Strong and moderate CYP3A inhibitors increased the exposure of abemaciclib plus its active metabolites to a clinically meaningful extent and may lead to increased toxicity. Avoid concomitant use of ketoconazole. Ketoconazole is predicted to increase the AUC of abemaciclib by up to 16-fold. In patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the Verzenio dose to 100 mg twice daily with concomitant use of strong CYP3A inhibitors other than ketoconazole. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the Verzenio dose to 50 mg twice daily with concomitant use of strong CYP3A inhibitors. If a patient taking Verzenio discontinues a strong CYP3A inhibitor, increase the Verzenio dose (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the inhibitor. Patients should avoid grapefruit products. With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the Verzenio dose in 50 mg decrements.

Avoid concomitant use of strong or moderate CYP3A inducers and consider alternative agents. Coadministration of strong or moderate CYP3A inducers decreased the plasma concentrations of abemaciclib plus its active metabolites and may lead to reduced activity.

With severe hepatic impairment (Child-Pugh C), reduce the Verzenio dosing frequency to once daily. No dosage adjustments are necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B).

Please see full Prescribing Information and Patient Information for Verzenio.

VZ IN HCP ISI ALL APPR

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about sofetabart mipitecan as a potential treatment for ovarian cancer as well as other FRα-expressing solid tumors, olomorasib as a potential treatment for certain KRAS G12C-mutant advanced solid tumors, Retevmo (selpercatinib) as a treatment for advanced RET-mutant medullary thyroid cancer (MTC), and Verzenio (abemaciclib) as a treatment for certain HR+, HER2– breast cancers in the adjuvant and advanced or metastatic setting, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that any of these therapies will prove to be a safe and effective treatment or receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Endnotes & References

Bax, Heather J et al. "Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes." British journal of cancer vol. 128,2 (2023): 342-353. doi:10.1038/s41416-022-02031-x Scaranti, Mariana et al. "Exploiting the folate receptor α in oncology." Nature reviews. Clinical oncology vol. 17,6 (2020): 349-359. doi:10.1038/s41571-020-0339-5. Kalli, Kimberly R et al. "Folate receptor alpha as a tumor target in epithelial ovarian cancer." Gynecologic oncology vol. 108,3 (2008): 619-26. doi:10.1016/j.ygyno.2007.11.020. Viricel W, et al. Cancer Res. 2023;83(suppl 7):1544. Ji J, Wang C, Fakih M. Targeting KRAS G12C-mutated advanced colorectal cancer: Research and clinical developments. OncoTargets and Therapy. 2022;Volume 15:747-756. doi:10.2147/ott.s340392Peng S-B, Si C, Zhang Y, et al. Abstract 1259: Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor. Cancer Research. 2021;81(13_Supplement):1259-1259. doi:10.1158/1538-7445.am2021-1259Retevmo. Prescribing information. Lilly USA, LLC.Verzenio. Prescribing information. Lilly USA, LLC.Inluriyo. Prescribing information. Lilly USA, LLC.Refer to: Megan Talon; [email protected] (Media)
Michael Czapar; [email protected] (Investors)

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-showcase-advances-across-its-oncology-pipeline-at-the-2026-european-society-for-medical-oncology-esmo-congress-302911565.html

SOURCE Eli Lilly and Company

Credicorp (NYSE:BAP – Get Free Report) and Eastern Bankshares (NASDAQ:EBC – Get Free Report) are both finance companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Valuation & Earnings This table compares Credicorp and Eastern Bankshares”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Credicorp $8.01 billion 4.49 $1.94 billion $26.99 14.12 Eastern Bankshares $1.33 billion 3.62 $88.22 million $1.76 11.95 Credicorp has higher revenue and earnings than Eastern Bankshares. Eastern Bankshares is trading at a lower price-to-earnings ratio than Credicorp, indicating that it is currently the more affordable of the two stocks. Institutional and Insider Ownership 89.8% of Credicorp shares are held by institutional investors. Comparatively, 71.7% of Eastern Bankshares shares are held by institutional investors. 15.9% of Credicorp shares are held by insiders. Comparatively, 1.3% of Eastern Bankshares shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations This is a breakdown of recent ratings and target prices for Credicorp and Eastern Bankshares, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Credicorp 0 2 5 0 2.71 Eastern Bankshares 0 3 6 0 2.67 Credicorp currently has a consensus target price of $431.80, indicating a potential upside of 13.34%. Eastern Bankshares has a consensus target price of $24.86, indicating a potential upside of 18.20%. Given Eastern Bankshares’ higher probable upside, analysts plainly believe Eastern Bankshares is more favorable than Credicorp.

Volatility and Risk Credicorp has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Eastern Bankshares has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Dividends Credicorp pays an annual dividend of $14.48 per share and has a dividend yield of 3.8%. Eastern Bankshares pays an annual dividend of $0.60 per share and has a dividend yield of 2.9%. Credicorp pays out 53.6% of its earnings in the form of a dividend. Eastern Bankshares pays out 34.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Credicorp has increased its dividend for 3 consecutive years and Eastern Bankshares has increased its dividend for 5 consecutive years.

Profitability This table compares Credicorp and Eastern Bankshares’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Credicorp 25.04% 20.52% 2.87% Eastern Bankshares 25.12% 8.71% 1.24% Summary Credicorp beats Eastern Bankshares on 12 of the 17 factors compared between the two stocks.

About Credicorp (Get Free Report)

Credicorp Ltd. provides various financial, insurance, and health services and products primarily in Peru and internationally. It operates through Universal Banking, Insurance and Pensions, Microfinance, and Investment Banking and Equity Management segments. The Universal Banking segment grants various credits and financial instruments to individuals and legal entities; and various deposits and current accounts. The Insurance and Pensions segment issues insurance policies to cover losses in commercial property, transport, marine vessels, automobiles, life, health, and pensions; and management services for private pension funds. The Microfinance segment provides management of loans, deposits, and current accounts for small and microenterprises. The Investment Banking and Equity Management segment is involved in provision of brokerage and investment management services for corporations, institutional investors, governments, and foundations; structuring and placement of issues in the primary market; execution and negotiation of transactions in the secondary market; and structuring of securitization processes for corporate customers and manages mutual funds. The company was founded in 1889 and is headquartered in Lima, Peru.

(Get Free Report)

Eastern Bankshares, Inc. operates as the bank holding company for Eastern Bank that provides banking products and services primarily to retail, commercial, and small business customers. The company provides deposit accounts, interest checking accounts, money market accounts, savings accounts, and time certificates of deposit accounts. It also offers commercial and industrial, commercial real estate and construction, small business, residential real estate, and home equity loans; lines of credit; and other consumer loans comprising unsecured personal lines of credit, overdraft protection, automobile loans, home improvement loans, airplane loans, and other personal loans. In addition, the company provides trust, financial planning and portfolio management, automated lock box collection, cash management, and account reconciliation services; personal, business, and employee benefits insurance products. Eastern Bankshares, Inc. was founded in 1818 and is headquartered in Boston, Massachusetts.

Receive News & Ratings for Credicorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Credicorp and related companies with MarketBeat.com's FREE daily email newsletter.

State Street Corp increased its holdings in shares of Eastern Bankshares, Inc. (NASDAQ:EBC – Free Report) by 42.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,124,657 shares of the company’s stock after acquiring an additional 3,603,128 shares during the period. State Street Corp owned approximately 5.31% of Eastern Bankshares worth $269,652,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Eastern Bankshares in the second quarter valued at approximately $498,672,000. Jennison Associates LLC lifted its position in shares of Eastern Bankshares by 28.9% during the 1st quarter. Jennison Associates LLC now owns 6,846,216 shares of the company’s stock valued at $133,912,000 after buying an additional 1,535,094 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Eastern Bankshares by 12.2% during the 4th quarter. Geode Capital Management LLC now owns 5,427,922 shares of the company’s stock valued at $100,050,000 after buying an additional 592,012 shares in the last quarter. Bank of America Corp DE acquired a new stake in Eastern Bankshares in the 2nd quarter valued at $38,188,000. Finally, Bank of New York Mellon Corp acquired a new stake in Eastern Bankshares in the 2nd quarter valued at $37,479,000. Hedge funds and other institutional investors own 71.68% of the company’s stock.

Eastern Bankshares Trading Down 1.1% Shares of EBC opened at $21.14 on Thursday. Eastern Bankshares, Inc. has a 52-week low of $16.61 and a 52-week high of $23.77. The stock has a market cap of $4.83 billion, a PE ratio of 12.01 and a beta of 0.66. The firm’s fifty day moving average is $22.54 and its two-hundred day moving average is $21.09. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 0.09.

Eastern Bankshares (NASDAQ:EBC – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.03. Eastern Bankshares had a net margin of 25.12% and a return on equity of 8.71%. The firm had revenue of $316.01 million for the quarter, compared to the consensus estimate of $308.20 million. Research analysts forecast that Eastern Bankshares, Inc. will post 1.87 earnings per share for the current fiscal year. Eastern Bankshares Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 22nd. Shareholders of record on Tuesday, September 8th were paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, September 8th. Eastern Bankshares’s dividend payout ratio (DPR) is 34.09%.

Analyst Upgrades and Downgrades A number of equities analysts have weighed in on EBC shares. Keefe, Bruyette & Woods upped their price objective on shares of Eastern Bankshares from $23.00 to $25.00 and gave the stock an “outperform” rating in a research report on Monday, July 27th. Piper Sandler reiterated an “overweight” rating and issued a $26.00 target price (up from $24.00) on shares of Eastern Bankshares in a research report on Monday, July 27th. Weiss Ratings reissued a “buy (b)” rating on shares of Eastern Bankshares in a research note on Friday, August 7th. Wall Street Zen upgraded shares of Eastern Bankshares from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Finally, Hovde Group raised their price target on shares of Eastern Bankshares from $23.50 to $26.00 and gave the company an “outperform” rating in a research note on Monday, July 27th. Six equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.86.

View Our Latest Report on Eastern Bankshares

Insider Transactions at Eastern Bankshares In related news, insider Donald Westermann sold 23,005 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $21.43, for a total value of $492,997.15. Following the completion of the sale, the insider owned 22,565 shares of the company’s stock, valued at approximately $483,567.95. This trade represents a 50.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Luis Borgen sold 1,710 shares of Eastern Bankshares stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $22.71, for a total value of $38,834.10. Following the transaction, the director owned 20,475 shares in the company, valued at approximately $464,987.25. The trade was a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 68,609 shares of company stock worth $1,529,281 in the last ninety days. Insiders own 1.26% of the company’s stock.

Eastern Bankshares Company Profile (Free Report)

Eastern Bankshares, Inc is the bank holding company for Eastern Bank, a full-service financial institution headquartered in Boston, Massachusetts. Eastern Bank provides banking and financial services to individuals, families, businesses, nonprofit organizations and municipalities, with a focus on communities in eastern Massachusetts and southern New Hampshire.

The bank offers deposit accounts, residential and commercial lending, small-business banking, cash-management services, digital and mobile banking, wealth management and trust services.

Featured Articles Five stocks we like better than Eastern Bankshares Chips to Bots: Qualcomm’s Agentic AI Breakout Ciena Fell 40%—Now One Analyst Sees 50% Upside Energy Transfer Taps the AI Power Boom Viking’s Obesity Edge May Be Staying Power, Not Weight Loss Want to see what other hedge funds are holding EBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eastern Bankshares, Inc. (NASDAQ:EBC – Free Report).

Receive News & Ratings for Eastern Bankshares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eastern Bankshares and related companies with MarketBeat.com's FREE daily email newsletter.

Eastern Bankshares, Inc. (EBC) Barclays 24th Annual Global Financial Services Conference September 15, 2026 10:30 AM EDT

Company Participants

Denis Sheahan - CEO & Director
R. Rosato - CFO & Treasurer

Conference Call Participants

Jared David Shaw - Barclays Bank PLC, Research Division

Presentation

Jared David Shaw
Barclays Bank PLC, Research Division

Great. Thanks. Sorry for the delay, but we're happy to continue the discussion this morning with Eastern Bankshares. We have Denis Sheahan, the CEO; and David Rosato, the CFO, joining us. Thanks very much, guys.

Denis Sheahan
CEO & Director

Thanks for having us.

R. Rosato
CFO & Treasurer

Thank you.

Question-and-Answer Session

Jared David Shaw
Barclays Bank PLC, Research Division

I guess maybe starting off, Boston has really become one of the more competitive banking markets in the country, it feels like, with large nationals, super regionals and wealth managers all trying to gain share. How would you characterize the competitive landscape today? And where do you think Eastern is best positioned to compete?

Denis Sheahan
CEO & Director

So yes, I mean, the Greater Boston market has always been very competitive. There are lots of smaller mutuals in the market. As a matter of fact, most of the mutuals in the country are in the New England region. So it's not unusual that we have a lot of competition. And yes, the larger organizations are there and have professed interest in coming into the region if they're not already there. But we really like our position in the marketplace. We have $31 billion in banking assets. We're the #4 in terms of deposit market share. We have a sizable and growing wealth and private banking business. And the Eastern brand is so ingrained in the marketplace. This is -- it's our home turf. We work and live and make decisions right in that marketplace. So the brand is very well known, and we really like our position.

Joseph F. Casey, Director of Eastern Bankshares, Inc. (EBC +2.95%), sold 10,000 shares of common stock on Aug. 21, 2026, according to a recent SEC Form 4 filing.

Transaction summaryMetricValueTransaction value~$230,000Shares sold10,000Post-transaction shares (total)305,478Post-transaction shares (directly held)3,883Post-transaction shares (indirectly held)301,595Post-transaction value$6.95 millionTransaction value based on SEC Form 4 weighted average sale price ($22.96); post-transaction value based on Aug. 21, 2026, market close ($22.74).

Company snapshotEBC is a Boston-based financial services company with a market capitalization of $5.3 billion as of Aug. 21, 2026.The company operates as the bank holding company for Eastern Bank, providing banking, trust, and investment services to retail, commercial, and small business customers.Eastern Bankshares reported trailing twelve-month revenue of $1.4 billion and net income of $376.1 million as of the latest reporting period. The company employed 2,349 full-time staff as of Aug. 21, 2026, market close.

Key questionsHow does this sale relate to the director's total equity position?
The sale of 10,000 shares represents a 3% reduction in total holdings, leaving the director with a remaining stake of ~305,000 shares and an insider ownership level of 0.13%.What is the structural nature of the remaining holdings?
The vast majority of the equity is held indirectly, with post-trade holdings distributed across a trust (227,234 shares), a Traditional IRA (72,079 shares), and a Roth IRA (2,282 shares), while 3,883 shares are held directly.Was the transaction part of a pre-established plan?
The disposition was executed under a Rule 10b5-1 trading plan, which allows insiders to schedule stock sales in advance to manage personal financial goals on a predetermined basis.How has the stock performed leading up to this transaction?
The transaction occurred following a period of appreciation for Eastern Bankshares, which recorded a 43% one-year total return as of the Aug. 21, 2026, transaction date.Company OverviewMetricValueShare Price (as of market close 2026-08-21)$22.74Market Capitalization$5.3 billionRevenue (TTM)$1.4 billionNet Income (TTM)$376.1 millionCompany SnapshotEastern Bankshares operates as the bank holding company for Eastern Bank, providing comprehensive banking, trust, and investment services, including deposit accounts, interest checking accounts, money market accounts, savings accounts, and time certificates of deposit, alongside commercial and industrial lending products such as asset-based lending, commercial real estate financing, and construction lending.The company generates revenue from net interest income on its lending portfolio and deposit base, fee-based services from trust and investment advisory operations, and commercial banking products serving retail, commercial, and small-business customers across the United States.Eastern Bankshares primarily serves retail depositors, commercial enterprises, small business owners, and institutional clients seeking regional banking solutions with personalized service and community-focused financial products.Eastern Bankshares is a regional bank holding company with $5.3 billion in market capitalization and $1.4 billion in TTM revenue, demonstrating solid scale within the regional banking sector. The company maintains a diversified revenue model spanning deposit products, commercial lending, and trust services, positioning it competitively within the regional banking landscape. With 2,349 employees and headquarters in Boston, Eastern Bankshares leverages its regional presence and community banking heritage to compete effectively against larger national institutions while maintaining operational efficiency and customer-centric service delivery.

What this transaction means for investorsWhen reviewing insider transactions, average investors should be cautious before drawing any conclusions. After all, many insider sales are for ordinary reasons, such as prearranged sales or tax withholding. Therefore, it's always best to go back to basics and review a company's fundamentals to understand how it is performing as a business. Now, let's have a closer look at Eastern Bankshares (EBC).

To begin, EBC stock has underperformed the broader stock market over the last few years. Since 2021, the stock has generated a total return of 26%, equating to a compound annual growth rate (CAGR) of 4.7%. The S&P 500, meanwhile, has delivered an 80% total return, with a 12.5% CAGR.

Premium Feature

Moneyball Superscore

62/100

Today's Change

(

2.95

%) $

0.64

Current Price

$

22.14

As for its underlying metrics, most look quite solid. The company recently reported $310 million in revenue, a 24% year-over-year jump. Net interest margin (NIM), a key performance indicator for any regional bank, was 3.70%, indicating that the EBC is generating a good spread between the interest it pays on deposits and the interest it earns on loans. Finally, its price-to-earnings (P/E) multiple is 12.2x, a modest ratio indicating that the stock has room to appreciate.

As for concerns, there are some. For one, EBC is a regional bank, which makes it susceptible to regional economic conditions. In this case, that means the New England regional economy. If conditions were to deteriorate in this region, EBC's stock would likely suffer. Moreover, competition remains stiff in this region. In turn, EBC may be forced to pay higher interest rates on its deposits, which could put pressure on its NIM. Lastly, EBC has recently divested Eastern Insurance Group. That unit generated non-interest fee income for the company. With it now gone, EBC is more reliant on a favorable interest rate environment.

In short, EBC is a regional bank whose stock has underperformed the broader market in recent years. However, its fundamentals look good on paper. That said, EBC also carries some risk, given its concentration in the New England region and its vulnerability to interest rate volatility.

-

BOSTON--(BUSINESS WIRE)--Eastern Bankshares, Inc. (the “Company”) (Nasdaq: EBC), the holding company for Eastern Bank, today announced Denis Sheahan, Chief Executive Officer, and David Rosato, Chief Financial Officer, will participate in a fireside chat at the Barclays 24th Annual Global Financial Services Conference on Tuesday, September 15, 2026 at 10:30 am ET.

A live audio webcast of the fireside chat will be available on the Company’s Investor Relations website at investor.easternbank.com. A replay of the webcast will be available on the website following the event.

About Eastern Bank
Eastern Bankshares, Inc. is the holding company for Eastern Bank. Founded in 1818, Eastern Bank is Greater Boston’s leading local bank with more than 125 branch locations serving communities in eastern Massachusetts, southern and coastal New Hampshire, and Rhode Island. As of June 30, 2026, Eastern had approximately $31.1 billion in assets. Eastern provides a full range of banking and wealth management solutions for consumers and businesses of all sizes including through its Cambridge Trust Wealth Management and Private Banking Divisions, which include the largest bank-owned independent investment adviser in Massachusetts with $10.6 billion in assets under management. Eastern takes pride in its advocacy and community support that includes more than $240 million in charitable giving since 1994. An inclusive company, Eastern is comprised of deeply committed professionals who value relationships with their customers, colleagues and communities. For investor information, visit investor.easternbank.com.

More News From Eastern Bank

Back to Newsroom

Deutsche Bank AG acquired a new position in shares of Eastern Bankshares, Inc. (NASDAQ:EBC – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 227,804 shares of the company’s stock, valued at approximately $5,066,000. Deutsche Bank AG owned 0.10% of Eastern Bankshares at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Eastern Bankshares by 12.6% during the 4th quarter. Vanguard Group Inc. now owns 21,874,030 shares of the company’s stock worth $403,138,000 after acquiring an additional 2,440,017 shares during the period. UBS Group AG increased its stake in Eastern Bankshares by 249.9% in the fourth quarter. UBS Group AG now owns 1,810,225 shares of the company’s stock valued at $33,362,000 after acquiring an additional 1,292,857 shares during the last quarter. Algebris UK Ltd. increased its stake in Eastern Bankshares by 21.8% in the fourth quarter. Algebris UK Ltd. now owns 624,471 shares of the company’s stock valued at $11,514,000 after acquiring an additional 111,811 shares during the last quarter. Minerva Advisors LLC acquired a new position in Eastern Bankshares during the fourth quarter valued at approximately $1,153,000. Finally, Arrowstreet Capital Limited Partnership raised its position in Eastern Bankshares by 25.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,447,779 shares of the company’s stock valued at $28,319,000 after purchasing an additional 289,458 shares in the last quarter. 71.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In A number of brokerages have weighed in on EBC. Wall Street Zen raised Eastern Bankshares from a “sell” rating to a “hold” rating in a report on Sunday. Stephens downgraded Eastern Bankshares from an “overweight” rating to an “equal weight” rating and set a $24.00 price objective for the company. in a research report on Tuesday, July 28th. Seaport Research Partners reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Eastern Bankshares in a research note on Monday, July 27th. Hovde Group lifted their target price on Eastern Bankshares from $23.50 to $26.00 and gave the company an “outperform” rating in a research report on Monday, July 27th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Eastern Bankshares in a research note on Friday, August 7th. Six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.86.

Get Our Latest Stock Report on EBC Insider Transactions at Eastern Bankshares In related news, Director Luis Borgen sold 1,710 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $22.71, for a total value of $38,834.10. Following the completion of the transaction, the director owned 20,475 shares in the company, valued at $464,987.25. This trade represents a 7.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joseph F. Casey sold 10,000 shares of Eastern Bankshares stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $22.96, for a total transaction of $229,600.00. Following the sale, the director owned 72,079 shares in the company, valued at approximately $1,654,933.84. This represents a 12.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 23,419 shares of company stock worth $542,181 over the last three months. Insiders own 1.26% of the company’s stock.

Eastern Bankshares Stock Down 0.4% Shares of NASDAQ:EBC opened at $22.64 on Tuesday. The company has a fifty day moving average of $22.52 and a 200-day moving average of $20.94. The company has a market capitalization of $5.17 billion, a PE ratio of 12.86 and a beta of 0.68. The company has a debt-to-equity ratio of 0.09, a quick ratio of 0.90 and a current ratio of 0.90. Eastern Bankshares, Inc. has a 52-week low of $16.50 and a 52-week high of $23.77.

Eastern Bankshares (NASDAQ:EBC – Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.03. Eastern Bankshares had a return on equity of 8.71% and a net margin of 25.12%.The company had revenue of $316.01 million for the quarter, compared to the consensus estimate of $308.20 million. On average, equities analysts predict that Eastern Bankshares, Inc. will post 1.88 EPS for the current fiscal year.

Eastern Bankshares Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 22nd. Shareholders of record on Tuesday, September 8th will be given a $0.15 dividend. The ex-dividend date is Tuesday, September 8th. This represents a $0.60 annualized dividend and a yield of 2.7%. Eastern Bankshares’s dividend payout ratio (DPR) is currently 34.09%.

Eastern Bankshares Company Profile (Free Report)

Eastern Bankshares, Inc is the bank holding company for Eastern Bank, one of the oldest and largest mutual banks in the United States. Founded in 1818 as Salem Savings Bank and later rebranded as Eastern Bank in 1989, the company preserved its mutual ownership structure for more than two centuries. In March 2020, it completed an initial public offering and began trading on the Nasdaq under the ticker EBC, while continuing to emphasize its community-focused heritage.

Through its primary subsidiary, Eastern Bank, the company delivers a broad range of commercial and consumer banking products.

Read More Five stocks we like better than Eastern Bankshares Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Snowflake Could Be Headed for New Highs Despite Insider Selling MongoDB Is Surging—And the Next Catalyst Is Almost Here

Receive News & Ratings for Eastern Bankshares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eastern Bankshares and related companies with MarketBeat.com's FREE daily email newsletter.

Bank of New York Mellon Corp bought a new position in shares of Eastern Bankshares, Inc. (NASDAQ:EBC – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,685,203 shares of the company’s stock, valued at approximately $37,479,000. Bank of New York Mellon Corp owned 0.73% of Eastern Bankshares as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Royal Bank of Canada increased its position in Eastern Bankshares by 38.0% during the 1st quarter. Royal Bank of Canada now owns 198,421 shares of the company’s stock worth $3,254,000 after buying an additional 54,664 shares during the period. AQR Capital Management LLC bought a new stake in shares of Eastern Bankshares in the first quarter valued at about $954,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Eastern Bankshares by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 114,881 shares of the company’s stock valued at $1,884,000 after acquiring an additional 5,028 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Eastern Bankshares by 7.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 432,405 shares of the company’s stock valued at $7,091,000 after acquiring an additional 29,781 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Eastern Bankshares by 789.9% in the first quarter. Jane Street Group LLC now owns 545,589 shares of the company’s stock valued at $8,948,000 after acquiring an additional 484,277 shares in the last quarter. 71.68% of the stock is owned by institutional investors.

Insider Transactions at Eastern Bankshares In other Eastern Bankshares news, Director Joseph F. Casey sold 10,000 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $22.72, for a total transaction of $227,200.00. Following the completion of the transaction, the director owned 62,079 shares of the company’s stock, valued at approximately $1,410,434.88. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Luis Borgen sold 1,710 shares of the stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $22.71, for a total transaction of $38,834.10. Following the completion of the transaction, the director directly owned 20,475 shares of the company’s stock, valued at $464,987.25. This trade represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 35,197 shares of company stock worth $809,724. Company insiders own 1.26% of the company’s stock.

Analyst Ratings Changes EBC has been the subject of several analyst reports. Keefe, Bruyette & Woods lifted their price objective on shares of Eastern Bankshares from $23.00 to $25.00 and gave the stock an “outperform” rating in a research note on Monday, July 27th. Piper Sandler reissued an “overweight” rating and issued a $26.00 price objective (up from $24.00) on shares of Eastern Bankshares in a report on Monday, July 27th. Stephens lowered shares of Eastern Bankshares from an “overweight” rating to an “equal weight” rating and set a $24.00 target price on the stock. in a research report on Tuesday, July 28th. DA Davidson raised their target price on shares of Eastern Bankshares from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Finally, Seaport Research Partners reiterated a “buy” rating and issued a $27.00 price target on shares of Eastern Bankshares in a research report on Monday, July 27th. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.86. View Our Latest Report on Eastern Bankshares

Eastern Bankshares Stock Down 0.5% NASDAQ EBC opened at $22.29 on Friday. The business has a fifty day moving average price of $22.67 and a two-hundred day moving average price of $20.97. The company has a debt-to-equity ratio of 0.09, a current ratio of 0.90 and a quick ratio of 0.90. Eastern Bankshares, Inc. has a fifty-two week low of $16.61 and a fifty-two week high of $23.77. The stock has a market capitalization of $5.09 billion, a PE ratio of 12.66 and a beta of 0.68.

Eastern Bankshares (NASDAQ:EBC – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.03. Eastern Bankshares had a return on equity of 8.71% and a net margin of 25.12%.The company had revenue of $316.01 million for the quarter, compared to analyst estimates of $308.20 million. Equities analysts expect that Eastern Bankshares, Inc. will post 1.88 earnings per share for the current fiscal year.

Eastern Bankshares Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 22nd. Shareholders of record on Tuesday, September 8th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, September 8th. Eastern Bankshares’s payout ratio is currently 34.09%.

(Free Report)

Eastern Bankshares, Inc is the bank holding company for Eastern Bank, one of the oldest and largest mutual banks in the United States. Founded in 1818 as Salem Savings Bank and later rebranded as Eastern Bank in 1989, the company preserved its mutual ownership structure for more than two centuries. In March 2020, it completed an initial public offering and began trading on the Nasdaq under the ticker EBC, while continuing to emphasize its community-focused heritage.

Through its primary subsidiary, Eastern Bank, the company delivers a broad range of commercial and consumer banking products.

Read More Five stocks we like better than Eastern Bankshares 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop? Want to see what other hedge funds are holding EBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eastern Bankshares, Inc. (NASDAQ:EBC – Free Report).

Receive News & Ratings for Eastern Bankshares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eastern Bankshares and related companies with MarketBeat.com's FREE daily email newsletter.

BOSTON--(BUSINESS WIRE)--Eastern Bank has been recognized for the third consecutive year as a World's Top Disability Inclusive Business based on its performance on the Disability Index®, the leading global benchmark for disability inclusion in business. “We are honored to receive this recognition from Disability:IN and remain committed to building a workplace where everyone has the opportunity to contribute and drive our success,” said Bob Rivers, Executive Chair and Chair of the Board of Direc.

Posted by Defense World Staff on Jul 26th, 2026

Dimensional Fund Advisors LP decreased its stake in shares of Eastern Bankshares, Inc. (NASDAQ:EBC – Free Report) by 9.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,618,230 shares of the company’s stock after selling 933,930 shares during the period. Dimensional Fund Advisors LP owned 3.67% of Eastern Bankshares worth $168,565,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. KBC Group NV raised its position in shares of Eastern Bankshares by 36.5% in the 1st quarter. KBC Group NV now owns 7,932 shares of the company’s stock worth $155,000 after buying an additional 2,123 shares during the period. Jennison Associates LLC grew its position in Eastern Bankshares by 28.9% during the first quarter. Jennison Associates LLC now owns 6,846,216 shares of the company’s stock valued at $133,912,000 after acquiring an additional 1,535,094 shares during the period. Bessemer Group Inc. increased its stake in Eastern Bankshares by 36.2% during the first quarter. Bessemer Group Inc. now owns 357,493 shares of the company’s stock worth $6,993,000 after acquiring an additional 95,100 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Eastern Bankshares by 11.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 19,305 shares of the company’s stock worth $382,000 after acquiring an additional 1,975 shares during the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new position in shares of Eastern Bankshares in the 1st quarter worth about $317,000. Hedge funds and other institutional investors own 71.68% of the company’s stock.

Trending Headlines about Eastern Bankshares Here are the key news stories impacting Eastern Bankshares this week:

Positive Sentiment: Eastern Bankshares delivered a Q2 earnings beat, with EPS of $0.49 versus $0.46 expected and revenue of $316.0 million versus $308.2 million estimated. Article Title Positive Sentiment: The company declared a quarterly dividend of $0.15 per share, reinforcing its shareholder-return profile and yield appeal. Article Title Neutral Sentiment: Management’s Q2 earnings call transcript may provide additional color on loan growth, margins, and credit trends, but no major new catalyst was highlighted in the provided summary. Article Title Neutral Sentiment: Short-interest data showed no meaningful change in positioning, with reported short interest at 0 shares, offering little signal for near-term trading pressure. Wall Street Analysts Forecast Growth EBC has been the topic of several research analyst reports. Piper Sandler lifted their price objective on Eastern Bankshares from $23.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, June 26th. TD Cowen decreased their price target on shares of Eastern Bankshares from $23.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, April 27th. DA Davidson initiated coverage on shares of Eastern Bankshares in a research report on Friday, May 15th. They set a “buy” rating and a $24.00 price target for the company. Barclays lowered their price target on Eastern Bankshares from $23.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, April 27th. Finally, Stephens began coverage on Eastern Bankshares in a research report on Wednesday, April 15th. They issued an “overweight” rating and a $24.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.08.

Read Our Latest Report on Eastern Bankshares

Eastern Bankshares Trading Up 1.3% Shares of NASDAQ EBC opened at $22.92 on Friday. The stock’s 50 day moving average price is $21.18 and its two-hundred day moving average price is $20.45. Eastern Bankshares, Inc. has a 52-week low of $14.88 and a 52-week high of $23.53. The stock has a market capitalization of $5.30 billion, a P/E ratio of 13.02 and a beta of 0.67. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.16.

Eastern Bankshares (NASDAQ:EBC – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.03. Eastern Bankshares had a return on equity of 8.78% and a net margin of 25.12%.The business had revenue of $316.00 million for the quarter, compared to analyst estimates of $308.20 million. On average, analysts anticipate that Eastern Bankshares, Inc. will post 1.87 earnings per share for the current fiscal year.

Eastern Bankshares Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 22nd. Shareholders of record on Tuesday, September 8th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.60 dividend on an annualized basis and a yield of 2.6%. Eastern Bankshares’s dividend payout ratio (DPR) is currently 34.09%.

Insider Transactions at Eastern Bankshares In other Eastern Bankshares news, Director Luis Borgen sold 1,710 shares of Eastern Bankshares stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $22.71, for a total value of $38,834.10. Following the completion of the transaction, the director directly owned 20,475 shares in the company, valued at $464,987.25. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.26% of the stock is owned by corporate insiders.

About Eastern Bankshares (Free Report)

Eastern Bankshares, Inc is the bank holding company for Eastern Bank, one of the oldest and largest mutual banks in the United States. Founded in 1818 as Salem Savings Bank and later rebranded as Eastern Bank in 1989, the company preserved its mutual ownership structure for more than two centuries. In March 2020, it completed an initial public offering and began trading on the Nasdaq under the ticker EBC, while continuing to emphasize its community-focused heritage.

Through its primary subsidiary, Eastern Bank, the company delivers a broad range of commercial and consumer banking products.

See Also Five stocks we like better than Eastern Bankshares Telecom Earnings Reveal a Sector That Finally Looks Healthier Defense Earnings Show Readiness Now and Modernization Ahead Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off MarketBeat Week in Review – 07/20- 07/24

Receive News & Ratings for Eastern Bankshares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eastern Bankshares and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDimensional Fund Advisors LP Increases Stock Holdings in First Hawaiian, Inc. $FHB

NEXT HEADLINE »Dimensional Fund Advisors LP Buys 833,919 Shares of Gentex Corporation $GNTX

Eastern Bankshares NASDAQ: EBC reported record operating net income for the second quarter, supported by loan and deposit growth, margin expansion, higher fee revenue and expense reductions tied to the HarborOne integration.

Chief Executive Officer Denis Sheahan said operating net income increased 20% from the prior quarter and 30% from a year earlier, producing an operating return on average tangible common equity of 15.3%. The company also returned $106 million to shareholders through dividends and share repurchases during the quarter.

Get Eastern Bankshares alerts:

“Our results are a reflection of the priorities we have consistently communicated to investors, organically growing both banking and fee-based businesses and returning capital to shareholders,” Sheahan said.

Second-Quarter Results and Margin Trends Eastern reported GAAP net income of $105.2 million, or $0.48 per diluted share. Operating net income, which excluded $1.6 million of remaining HarborOne merger-related costs, was $106.5 million, or $0.49 per diluted share.

Chief Financial Officer David Rosato said operating revenue growth and expense management generated positive operating leverage. The operating efficiency ratio improved to 49%, while operating return on average assets increased 21 basis points to 1.38%.

Net interest income increased 3% from the first quarter as the net interest margin expanded 3 basis points to 3.66%. Higher yields on loans and securities more than offset increased funding costs, Rosato said. Total interest-earning asset yields rose 4 basis points, while interest-bearing liability costs increased 2 basis points.

Discount accretion remained about $20 million during the quarter and contributed 28 basis points to the margin. Rosato later said the company expects accretion income to remain around its recent quarterly run rate of roughly $19.5 million, with a potential slight decline over time.

Operating non-interest income rose $12.8 million, or 28%, from the first quarter. The largest contributor was an $8.9 million increase in investment income related to employee retirement benefits, reflecting stronger equity markets. That gain was partly offset by a $3.4 million increase in related employee benefit costs.

The company also cited higher investment advisory fees, seasonal tax preparation fees and increased interest-rate swap income. Rosato said swap income benefited from higher commercial loan volume and greater customer use of interest-rate risk-management products.

Loan, Deposit and Wealth Management Growth Period-end loan balances increased $325 million, or 1.4%, from the preceding quarter. More than $300 million of commercial and industrial loan growth drove the increase, partially offset by commercial real estate payoffs.

Sheahan said the commercial lending pipeline finished June at a record level and was diversified across businesses. Rosato put the commercial pipeline at nearly $1 billion. Management said it expects commercial real estate payoffs, which were elevated in the second quarter, to moderate during the second half of the year.

Home equity balances rose $59 million, while residential mortgage balances declined slightly. Rosato said Eastern expects its residential mortgage portfolio to remain relatively flat in 2026 as it emphasizes home equity and commercial lending growth.

Deposits increased $814 million, or 3.2%, from the prior quarter, driven by seasonal municipal inflows and broad-based growth across business lines. The loan-to-deposit ratio improved to 91% at quarter-end from 93% at March 31.

Management expects a portion of municipal deposits to leave seasonally in the third quarter. Total deposit costs increased 1 basis point to 1.47%, while the June spot deposit rate was 1.51%, reflecting competition in the New England deposit market.

Rosato said competition remains relatively constant and does not expect it to ease in the near term. The company expects money market balances to grow faster than certificates of deposit, citing customer preference for money market products.

Wealth management assets reached a record $11.5 billion. Sheahan said the business provides recurring fee income, diversifies earnings and deepens customer relationships, particularly through coordination among wealth management, private banking and commercial banking teams.

Credit Quality, Costs and Capital Return Asset quality remained strong, according to management. Net charge-offs were stable at 17 basis points of average total loans. Nonperforming loans declined $29 million from the first quarter to $109 million, or 47 basis points of total loans.

Sheahan said Eastern has limited exposure to life-science lending and continues to monitor its office portfolio closely. He said every office loan above $5 million is re-underwritten annually.

Non-interest expense declined $30.7 million, or 15%, from the first quarter. Most of the reduction reflected lower merger-related costs, while operating non-interest expense declined $1.5 million. Rosato said HarborOne cost savings are “basically done,” with savings primarily reflected in salaries and benefits as well as occupancy and equipment costs.

Eastern paid $33.1 million in dividends and repurchased 3.6 million shares for $72.7 million during the quarter, at an average price of $20.03 per share. Its CET1 ratio was 13% and its tangible common equity ratio was 10.1% at June 30.

The board authorized a new repurchase program for up to 11.3 million shares, equivalent to 5% of common shares outstanding, through Dec. 31, 2027. The board also approved a $0.15 per-share dividend payable in September.

Updated 2026 Outlook Eastern narrowed its full-year loan growth outlook to 3% to 4%, from a previous range of 3% to 5%, reflecting a slower start to the year. It raised its deposit growth outlook to 2% to 3%, from 1% to 2%.

The company also lowered its outlook for net interest income and margin, citing softer first-quarter loan growth, lower-than-expected accretion income and deposit competition. Management expects full-year fully taxable equivalent net interest margin of 3.60% to 3.65%.

Eastern reduced its expected provision for credit losses to $25 million to $30 million, from $30 million to $40 million, citing favorable credit performance. It narrowed its operating fee income outlook to $195 million to $200 million and tightened its operating non-interest expense range to $655 million to $665 million.

About Eastern Bankshares (NASDAQ:EBC)Eastern Bankshares, Inc is the bank holding company for Eastern Bank, one of the oldest and largest mutual banks in the United States. Founded in 1818 as Salem Savings Bank and later rebranded as Eastern Bank in 1989, the company preserved its mutual ownership structure for more than two centuries. In March 2020, it completed an initial public offering and began trading on the Nasdaq under the ticker EBC, while continuing to emphasize its community-focused heritage.

Through its primary subsidiary, Eastern Bank, the company delivers a broad range of commercial and consumer banking products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Eastern Bankshares Right Now?Before you consider Eastern Bankshares, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eastern Bankshares wasn't on the list.

While Eastern Bankshares currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Eastern Bankshares, Inc. (EBC - Free Report) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +6.52%. A quarter ago, it was expected that this company would post earnings of $0.44 per share when it actually produced earnings of $0.4, delivering a surprise of -9.09%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Eastern Bankshares, which belongs to the Zacks Banks - Northeast industry, posted revenues of $309.5 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.70%. This compares to year-ago revenues of $244.9 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Eastern Bankshares shares have added about 22.5% since the beginning of the year versus the S&P 500's gain of 9.6%.

What's Next for Eastern Bankshares?While Eastern Bankshares has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Eastern Bankshares was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.49 on $311.85 million in revenues for the coming quarter and $1.87 on $1.22 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Northeast is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Peapack-Gladstone (PGC - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on July 27.

This bank holding company is expected to post quarterly earnings of $0.87 per share in its upcoming report, which represents a year-over-year change of +93.3%. The consensus EPS estimate for the quarter has been revised 2.7% higher over the last 30 days to the current level.

Peapack-Gladstone's revenues are expected to be $85.84 million, up 23.1% from the year-ago quarter.

In its upcoming report, Eastern Bankshares, Inc. (EBC - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.46 per share, reflecting an increase of 12.2% compared to the same period last year. Revenues are forecasted to be $304.32 million, representing a year-over-year increase of 24.3%.

Over the last 30 days, there has been a downward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

With that in mind, let's delve into the average projections of some Eastern Bankshares metrics that are commonly tracked and projected by analysts on Wall Street.

According to the collective judgment of analysts, 'Efficiency ratio (GAAP)' should come in at 53.0%. Compared to the present estimate, the company reported 55.9% in the same quarter last year.

Analysts predict that the 'Net interest margin (FTE)' will reach 3.7%. Compared to the present estimate, the company reported 3.6% in the same quarter last year.

Analysts' assessment points toward 'Average Balance - Total interest-earning assets' reaching $28.39 billion. The estimate is in contrast to the year-ago figure of $23.14 billion.

The average prediction of analysts places 'Total non-performing assets' at $137.70 million. Compared to the present estimate, the company reported $54.70 million in the same quarter last year.

Analysts expect 'Total regulatory capital (to risk-weighted assets)' to come in at 14.3%. Compared to the current estimate, the company reported 15.5% in the same quarter of the previous year.

The consensus estimate for 'Tier 1 capital (to average assets) leverage' stands at 11.5%. The estimate is in contrast to the year-ago figure of 12.1%.

Analysts forecast 'Tier 1 capital (to risk-weighted assets)' to reach 12.8%. Compared to the current estimate, the company reported 14.4% in the same quarter of the previous year.

Based on the collective assessment of analysts, 'Total non-performing loans' should arrive at $137.70 million. The estimate compares to the year-ago value of $54.70 million.

It is projected by analysts that the 'Net Interest Income' will reach $255.62 million. Compared to the present estimate, the company reported $202.00 million in the same quarter last year.

The collective assessment of analysts points to an estimated 'Total Noninterest Income' of $48.38 million. Compared to the current estimate, the company reported $42.90 million in the same quarter of the previous year.

The combined assessment of analysts suggests that 'Investment advisory fees' will likely reach $19.12 million. The estimate compares to the year-ago value of $17.30 million.

The consensus among analysts is that 'Net Interest Income (FTE)' will reach $258.99 million. The estimate compares to the year-ago value of $206.80 million.

View all Key Company Metrics for Eastern Bankshares here>>>

Shares of Eastern Bankshares have experienced a change of +9.3% in the past month compared to the +0.3% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), EBC is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

-

BOSTON--(BUSINESS WIRE)--Eastern Bankshares, Inc. (the “Company”) (NASDAQ: EBC), the holding company for Eastern Bank, today announced the following details regarding the report of the Company’s second quarter 2026 results:

Earnings Release:

Thursday, July 23, 2026 after the market close

Conference Call:

Friday, July 24, 2026 at 9:00 AM Eastern Time

Join by Telephone:

Toll-Free Dial-In Number: (833) 461-5787

Conference ID: 875195656

Webcast:

The conference call will be simultaneously webcast. Participants may join the webcast on the Company’s Investor Relations website at investor.easternbank.com. A replay of the webcast will be made available on demand on this site.

About Eastern Bankshares, Inc.
Eastern Bankshares, Inc. is the holding company for Eastern Bank. Founded in 1818, Eastern Bank is Greater Boston’s leading local bank with more than 125 branch locations serving communities in eastern Massachusetts, southern and coastal New Hampshire, and Rhode Island. As of March 31, 2026, Eastern had approximately $30.6 billion in assets. Eastern provides a full range of banking and wealth management solutions for consumers and businesses of all sizes including through its Cambridge Trust Wealth Management and Private Banking Divisions, which include the largest bank-owned independent investment adviser in Massachusetts with $9.8 billion in assets under management. Eastern takes pride in its advocacy and community support that includes more than $240 million in charitable giving since 1994. An inclusive company, Eastern is comprised of deeply committed professionals who value relationships with their customers, colleagues and communities. For investor information, visit investor.easternbank.com.

More News From Eastern Bank

Back to Newsroom

BOSTON--(BUSINESS WIRE)--Eastern Bank is pleased to announce financing for 775 Huntington Avenue, a new mixed-income residential development located in the Mission Hill neighborhood of Boston. Sponsored by Roxbury Tenants of Harvard (RTH), the project will create 55 mixed-income homeownership units, comprised of 27 affordable homes and 28 market‑rate homes, and 57 affordable rental units within a new 13‑story building that also includes commercial space and structured parking. Eastern is servin.

BOSTON--(BUSINESS WIRE)--Eastern Bankshares, Inc. Announces First Quarter 2026 Earnings Release Date, Conference Call and Webcast.

Eastern Bankshares, Inc. (EBC - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 23. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis company is expected to post quarterly earnings of $0.44 per share in its upcoming report, which represents a year-over-year change of +29.4%.

Revenues are expected to be $299.63 million, up 34.7% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.42% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Eastern Bankshares?For Eastern Bankshares, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -4.11%.

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination makes it difficult to conclusively predict that Eastern Bankshares will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Eastern Bankshares would post earnings of $0.41 per share when it actually produced earnings of $0.44, delivering a surprise of +7.32%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Eastern Bankshares doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

BOSTON--(BUSINESS WIRE)--Eastern Bankshares, Inc. Reports First Quarter 2026 Financial Results.

For the quarter ended March 2026, Eastern Bankshares, Inc. (EBC - Free Report) reported revenue of $288.3 million, up 29.6% over the same period last year. EPS came in at $0.40, compared to $0.34 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $299.63 million, representing a surprise of -3.78%. The company delivered an EPS surprise of -8.68%, with the consensus EPS estimate being $0.44.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Eastern Bankshares performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Efficiency ratio (GAAP): 68.9% versus 55.8% estimated by five analysts on average.Net interest margin (FTE): 3.6% versus 3.6% estimated by five analysts on average.Average Balance - Total interest-earning assets: $28.01 billion compared to the $28.38 billion average estimate based on four analysts.Total non-performing assets: $137.7 million versus $180.92 million estimated by two analysts on average.Total Noninterest Income: $43.6 million versus the five-analyst average estimate of $47.92 million.Net Interest Income: $244.7 million compared to the $252.11 million average estimate based on five analysts.Interest rate swap income: $1 million versus the three-analyst average estimate of $1.41 million.Card Income: $5.8 million compared to the $5.77 million average estimate based on three analysts.Investment advisory fees: $18.3 million versus the three-analyst average estimate of $18 million.Service charges on deposit accounts: $9.9 million versus $10.65 million estimated by three analysts on average.Other non-operating (loss) income: $-1.5 million versus $6.99 million estimated by two analysts on average.Net Interest Income (FTE): $250.8 million versus the two-analyst average estimate of $255.16 million.View all Key Company Metrics for Eastern Bankshares here>>>

Shares of Eastern Bankshares have returned +4.5% over the past month versus the Zacks S&P 500 composite's +9.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

BOSTON--(BUSINESS WIRE)--Eastern Bank today announced a key leadership update within its Commercial Lending Team. Senior Vice President Yongmei Chen has been promoted to Commercial Group Director of Community Development Lending. She succeeds Pamela Feingold, who served in the role until her passing on March 16, 2026. Ms. Chen is a long-tenured Eastern commercial lending leader with over 30 years of banking experience, and has held numerous leadership positions since joining Eastern in 2007. Sh.

🚀 Enjoy a 7-Day Free Trial Thru Jun 19, 2026! ✨

Menu

Categories

No Data

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Follow Us

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.

© 2004-2026 GuruFocus.com, LLC. All Rights Reserved.

BOSTON--(BUSINESS WIRE)--Eastern Bank today announced it has provided financing to support the conversion of Surety Bond Professionals (SBP), a Massachusetts-based, independent surety-only agency, to a 100% employee-owned company. The financing includes a term loan to facilitate the establishment of an Employee Stock Ownership Plan (ESOP), a revolving line of credit to support the company's ongoing working capital needs, cash management solutions, as well as the availability of a comprehensive.